ALTS

ALT5 Sigma Corporation operates as a specialty pharmaceutical company focused on developing and commercializing innovative drug delivery technologies and pharmaceutical products. Headquartered in Atlanta, Georgia, the company concentrates primarily on sterile injectable pharmaceuticals and alternative dosage forms that address unmet medical needs. ALTS leverages its proprietary NanoCrystal technology platform, which enhances the bioavailability and therapeutic effectiveness of poorly soluble drug compounds. The company's product portfolio includes both proprietary formulations and partnered products developed for pharmaceutical clients seeking to improve existing medications or extend product lifecycles. ALTS operates manufacturing facilities that comply with FDA Good Manufacturing Practice standards, serving both its internal pipeline and contract development clients. The company generates revenue through product sales, licensing agreements, and development partnerships with larger pharmaceutical companies. In recent developments, ALTS has focused on expanding its pipeline of ready-to-use injectable products, addressing supply chain challenges in critical hospital medications. The company maintains strategic collaborations with multiple pharmaceutical partners who utilize its formulation expertise and manufacturing capabilities. As a small-cap pharmaceutical firm, ALTS competes in niche segments of the drug delivery market where its specialized technology platforms provide differentiation from generic manufacturers while offering cost-effective alternatives to more complex delivery systems.